Overview

Chronic Kidney Disease Diagnostics Market Introduction:

Chronic kidney disease symptoms like blood in urine, swollen joints, foamy urine, etc are seldom noticed by patients resulting in progressive loss of kidney functions and ultimately renal failure. Delayed diagnosis, lack of sufficient epidemiological data, the significant cost involved in end-stage renal diseases as well as mild kidney diseases have resulted in a substantial need for chronic kidney disease diagnostics. Apart from physical examination by healthcare professionals, certain diagnostics like biopsy or procedures like blood and urine test provide vital stats and early signs about patients neurological, blood vessels and organ conditions. Based on such diagnostic results healthcare professionals can effectively control the kidney symptoms and avoid the progression of chronic kidney disease in their patients.

Chronic Kidney Disease Diagnostics Market Overview

Factors boosting the chronic kidney disease diagnostics market:
•    Rising prevalence of kidney diseases
•    Increase in diabetic patients’ population 
•    Investments into R&D for kidney diseases diagnostic techniques
•    The ever-emerging healthcare sector 
•    Extensive use of processed food containing excess potassium and
•    The technological advancements in the healthcare diagnostics sector

Besides increased susceptibility of the ageing population due to degrading immune system, diabetics, cardiovascular issues are expected to fuel the growth of the global chronic kidney diseases diagnostics market during the forecast period.

North America holds the major revenue chunk in the global kidney diseases diagnostics market and is expected to grow at a thriving CAGR during the forecast period of 2019-2026. This is followed by Europe due to robust economic growth and investments in advanced diagnostic technologies. India, China and Vietnam from the APAC region are expected to demonstrate tremendous opportunities due to increased healthcare awareness, better household incomes and government aids to healthcare institutions. Rest of the world is expected to grow at a gradual CAGR and considerable market value in coming years. 

Key Market Players Abbott Laboratories, AbbVie Inc., Amgen Inc., Beckman Coulter, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Pfizer Inc, Siemens Healthineers, Sysmex Corporation, Teva Pharmaceutical Industries Ltd.

Chronic Kidney Disease Diagnostics Market Segmentation:

By Product Type

• By Diagnosis
   o Blood Tests
   o Urine Tests
   o Imaging Tests
   o Others
• By Treatment
   o Drug Class
         o ACE Inhibitors
         o Angiotensin-II Receptor Blockers
         o Diuretics
      ​​​​​​​   o Other
​​​​​​​   o Dialysis​​​​​​​
​​​​​​​   o Other

By End-User

•    Hospitals
•    Clinics
•    Diagnostic labs 

By Region

•    North America
•    Latin America
•    Europe
•    Asia Pacific
•    Middle East and Africa
Competitive Landscape:  
•    Tier 1 players- established companies in the market with a major market share
•    Tier 2 players 
•    Emerging players which are growing rapidly 
•    New Entrants  

FutureWise Key Takeaways 
•    Growth prospects
•    SWOT analysis 
•    Key trends 
•    Key data-points affecting market growth 

Objectives of the Study: 
•    To provide with an exhaustive analysis on the global chronic kidney disease diagnostics market on the basis of product type, end user, and region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and Middle East and Africa
•    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
•    Profiling of companies to evaluate their market shares, strategies, financials and core competencies  

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
 

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
    2.1. Research Data 
         2.1.1. Secondary Data
                2.1.1.1. Key Data from Secondary Sources
         2.1.2. Primary Data
                2.1.2.1. Key Data from Primary Sources
    2.2. Market Size Estimation 
    2.3. Market Breakdown and Data Triangulation 
    2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Chronic Kidney Disease Diagnostics Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Type Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Chronic Kidney Disease Diagnostics Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Chronic Kidney Disease Diagnostics Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Type Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Type Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Chronic Kidney Disease Diagnostics Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. By Diagnosis
        7.1.1. Blood Tests
        7.1.2. Urine Tests
        7.1.3. Imaging Tests
        7.1.4. Others
   7.2. By Treatment
        7.2.1. Drug Class
               7.2.1.1. ACE Inhibitors
               7.2.1.2. Angiotensin-II Receptor Blockers
               7.2.1.3. Diuretics
               7.2.1.4. Other
        7.2.2. Dialysis
        7.2.3. Other

8. Chronic Kidney Disease Diagnostics Market, By End-User Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Hospitals 
   8.2. Clinics
   8.3. Diagnostic labs

9. North America Chronic Kidney Disease Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   9.1. Introduction
   9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
        9.2.1. U.S.A
        9.2.2. Canada
        9.2.3. Mexico
   9.3. Market Size (USD Million) Forecast for North America 2022-2028

10. Latin America Chronic Kidney Disease Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. Brazil
          10.2.2. Venezuela
          10.2.3. Argentina
          10.2.4. Rest of Latin America
    10.3. Market Size (USD Million) Forecast for Latin America 2022-2028

11. Europe Chronic Kidney Disease Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Germany
          11.2.2. U.K         
          11.2.3. France
          11.2.4. Italy
          11.2.5. Spain
          11.2.6. Russia
          11.2.7. Poland
          11.2.8. Rest of Europe
    11.3. Market Size (USD Million) Forecast for Europe 2022-2028

12. Asia Pacific Chronic Kidney Disease Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Japan
          12.2.2. China
          12.2.3. India
          12.2.4. Australia and New Zealand
          12.2.5. ASEAN
          12.2.6. Rest of Asia Pacific
    12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

13. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. GCC
          13.2.2. Israel
          13.2.3. South Africa
          13.2.4. Rest of MEA
    13.3. Market Size (USD Million) Forecast for MEA 2022-2028

14. Market Share Analysis and Competitive Landscape   
    14.1. Global Landscape - Key Players, Revenue and Presence
    14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    14.3. Global Emerging Companies
    14.4. North America - Market Share Analysis and Key Regional Players
    14.5. Europe - Market Share Analysis and Key Regional Players
    14.6. Asia Pacific - Market Share Analysis and Key Regional Players
    14.7. Global Key Player - Growth Matrix

15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    15.1. Abbott Laboratories
          15.1.1. Company Overview
          15.1.2. Product Portfolio
          15.1.3. SWOT Analysis
          15.1.4. Financial Overview
          15.1.5. Strategic Overview
    15.2. AbbVie Inc
          15.2.1. Company Overview
          15.2.2. Product Portfolio
          15.2.3. SWOT Analysis
          15.2.4. Financial Overview
          15.2.5. Strategic Overview                         
    15.3. Amgen Inc
          15.3.1. Company Overview
          15.3.2. Product Portfolio
          15.3.3. SWOT Analysis
          15.3.4. Financial Overview
          15.3.5. Strategic Overview
    15.4. Beckman Coulter
          15.4.1. Company Overview
          15.4.2. Product Portfolio
          15.4.3. SWOT Analysis
          15.4.4. Financial Overview
          15.4.5. Strategic Overview
    15.5. F. Hoffmann-La Roche Ltd
          15.5.1. Company Overview
          15.5.2. Product Portfolio
          15.5.3. SWOT Analysis
          15.5.4. Financial Overview
          15.5.5. Strategic Overview          
    15.6. GlaxoSmithKline Plc
          15.6.1. Company Overview
          15.6.2. Product Portfolio
          15.6.3. SWOT Analysis
          15.6.4. Financial Overview
          15.6.5. Strategic Overview      
    15.7. Pfizer, Inc.
          15.7.1. Company Overview
          15.7.2. Product Portfolio
          15.7.3. SWOT Analysis
          15.7.4. Financial Overview
          15.7.5. Strategic Overview
    15.8. Siemens Healthineers
          15.8.1. Company Overview
          15.8.2. Product Portfolio
          15.8.3. SWOT Analysis
          15.8.4. Financial Overview
          15.8.5. Strategic Overview 
    15.9. Sysmex Corporation
          15.9.1. Company Overview
          15.9.2. Product Portfolio
          15.9.3. SWOT Analysis
          15.9.4. Financial Overview
          15.9.5. Strategic Overview 
    15.10.Teva Pharmaceutical Industries Ltd.      
          15.10.1. Company Overview
          15.10.2. Product Portfolio
          15.10.3. SWOT Analysis
          15.10.4. Financial Overview
          15.10.5. Strategic Overview 

16. Pre and Post COVID-19 Impact
    16.1. Positive influence on the healthcare industry
    16.2. The financial disruption of the manufacturing sector
    16.3. Impact of COVID-19 on emerging companies
    16.4. Significant mandates in the healthcare regulations initiated by administrations
    16.5. The overall economic slowdown of the developing and developed nations

17. FutureWise SME Key Takeaway Points for Client

Tables

Figures